Sugi Predict

Sugi Predict / Compounds / SCHEMBL560223

SCHEMBL560223

SCHEMBL560223

O=C(O)C(C[C@](O)(Cc1c[nH]c2ccccc12)C(=O)O)=NO

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.49
▸ MEN1 O00255 6/20 0.49
▸ MAPT P10636 5/20 0.49
▸ KDM4E B2RXH2 4/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ HPGD P15428 1/20 0.49
▸ SLC6A2 P23975 1/20 0.44
▸ FNTA P49354 1/20 0.44
▸ FNTB P49356 1/20 0.44
▸ LMNA P02545 2/20 0.43
▸ APAF1 O14727 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ MPO P05164 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ BLM P54132 1/20 0.43
▸ PMP22 Q01453 1/20 0.43
▸ HIF1A Q16665 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560021 1.00 KMT2A (0.49) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL10088120 1.00 KMT2A (0.49) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL559737 1.00 KMT2A (0.49) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL560022 1.00 KMT2A (0.49) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL10088118 1.00 KMT2A (0.49) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL13844616 1.00 KMT2A (0.49) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL12169853 1.00 KMT2A (0.49) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL559736 1.00 KMT2A (0.49) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL560222 1.00 KMT2A (0.49) KMT2AMEN1MAPTKDM4ESMN1; SMN2
Ammonia Solution, Strong SCHEMBL560400 0.99 KMT2A (0.48) KMT2AMEN1MAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1719758-B1 PROCESS FOR PRODUCING MONATIN AJINOMOTO KK (JP) 2012-02-22 — — EP disclosed
US-20120035373-A1 PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES AJINOMOTO CO. INC (JP) 2012-02-09 — — US disclosed
US-8048647-B2 Aldolase, and method for producing optically active IHOG and monatin AJINOMOTO CO., INC. (JP) 2011-11-01 — — US disclosed
US-7868187-B2 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes AJINOMOTO CO., INC. (JP) 2011-01-11 — — US disclosed
US-7868187-B2 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes AJINOMOTO CO., INC. (JP) 2011-01-11 — — US disclosed
US-20100184165-A1 NOVEL ALDOLASE, AND METHOD FOR PRODUCING OPTICALLY ACTIVE IHOG AND MONATIN AJINOMOTO CO., INC. (JP) 2010-07-22 — — US disclosed
US-20100105924-A1 PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES AJINOMOTO CO. INC. (JP) 2010-04-29 — — US disclosed
US-20100105924-A1 PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES AJINOMOTO CO. INC. (JP) 2010-04-29 — — US disclosed
US-7678925-B2 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes AJINOMOTO CO., INC. (JP) 2010-03-16 — — US disclosed
US-7662596-B2 Aldolase, and method for producing optically active IHOG and monatin AJINOMOTO CO., INC. (JP) 2010-02-16 — — US disclosed
US-20070066832-A1 Simultaneous isomerization at position 2 of monatin having different configurations at positions 2 and 4 in the presence of an aldehyde in a solvent mixture of alcohol and water and crystallization to produce an optical isomer of monatin that has the same configurations at positions 2 and 4 or salt . AJINOMOTO CO., INC. (JP) 2007-03-22 — — US disclosed
EP-1719758-A1 PROCESS FOR PRODUCING MONATIN Ajinomoto Co., Inc. (JP) 2006-11-08 — — EP disclosed
US-20060172396-A1 Novel aldolase, and method for producing optically active IHOG and monatin AJINOMOTO CO., INC. (JP) 2006-08-03 — — US disclosed
US-7064219-B2 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes AJINOMOTO CO., INC. (JP) 2006-06-20 — — US disclosed
US-20060074249-A1 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes AJINOMOTO CO. INC (JP) 2006-04-06 — — US disclosed
CN-1749402-A Novel aldolase, and method for producing optically active ihog and monatin AJINOMOTO KK (JP) 2006-03-22 — — CN disclosed
US-20060003426-A1 Novel aldolase, and method for producing optically active IHOG and monatin AJINOMOTO CO., INC. (JP) 2006-01-05 — — US disclosed
EP-1605041-A2 Aldolase, and method for producing optically active IHOG and monatin Ajinomoto Co., Inc. (JP) 2005-12-14 — — EP disclosed
US-20050004394-A1 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes AJINOMOTO CO. IN (JP) 2005-01-06 — — US disclosed
EP-1466890-A1 PROCESSES FOR THE PREPARATION OF GLUTAMIC ACID COMPOUNDS AND INTERMEDIATES THEREOF AND NOVEL INTERMEDIATES USED IN THE PROCESSES Ajinomoto Co., Inc. (JP) 2004-10-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035373-A1 PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES GLUL, MON2, GRIK5 KMT2A 1562/4885MEN1 62/4885MAPT 1029/4885
US-20050004394-A1 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes GLUL, MON2, GRIK5 KMT2A 1562/4885MEN1 62/4885MAPT 1029/4885
US-20070066832-A1 Simultaneous isomerization at position 2 of monatin having different configurations at positions 2 and 4 in the presence of an aldehyde in a solvent mixture of alcohol and water and crystallization to produce an optical isomer of monatin that has the same configurations at positions 2 and 4 or salt . MON2, SORD, MAN2B2 KMT2A 1981/4885MEN1 305/4885MAPT 387/4885
US-20100105924-A1 PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES GLUL, MON2, GRIK5 KMT2A 1562/4885MEN1 62/4885MAPT 1029/4885
US-20060074249-A1 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes GLUL, MON2, GRIK5 KMT2A 1562/4885MEN1 62/4885MAPT 1029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.